Amylin to present data on investigational diabetes drug candidates at ADA annual meeting

Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that the Company will present data for its two first-in-class diabetes drugs, BYETTA® (exenatide) injection and SYMLIN® (pramlintide acetate) injection, and its investigational diabetes drug candidates BYDUREON™ (exenatide extended-release for injectable suspension) and exenatide once monthly at the 71st Scientific Sessions of the American Diabetes Association (ADA) being held in San Diego, CA from June 24 to June 28. The Company will also host an investor presentation and webcast on Sunday, June 26 at 7:30 PM PT/10:30 PM ET.

The annual meeting of the ADA is one of the largest scientific meetings for endocrinologists and other health care professionals involved in diabetes research and diabetes care. Amylin will introduce data through two oral presentations and 17 posters at the meeting. The data presented will demonstrate significant progress and new insights concerning the scientific basis and clinical utility of BYETTA, BYDUREON and SYMLIN. Additional information will be presented during a corporate symposium focused on making clinical decisions in the ever-changing environment of incretin therapies.

"We look forward to providing updates that further demonstrate the compelling safety and efficacy profiles of Amylin's approved therapies, BYETTA and SYMLIN, and our investigational candidate, BYDUREON," said Daniel M. Bradbury, president and chief executive officer of Amylin Pharmaceuticals, Inc. "As one of the foremost gatherings of the diabetes community, we anticipate that the presentations and discussions at this year's ADA Scientific Sessions will showcase innovative research and treatment approaches that have the potential to transform the way diabetes is treated and improve the lives of the millions of people living with this chronic disease."

Amylin will post insights throughout the conference on its newly launched corporate blog, "Building Blocks" (www.amylinbuildingblocks.com). Building on the success of last year's Amylin ADA Online Summit, the blog will feature perspectives from Amylin leadership and global experts on key issues facing the diabetes community, and the latest innovations that could shape the future of diabetes care. New entries will be posted throughout the conference, and will continue on a regular basis after the conference concludes.

Key Amylin Abstracts Being Presented at ADA

1. Oral: "DURATION-3: Efficacy of Exenatide Once Weekly (EQW) and Insulin Glargine QD (IG) After 84 Weeks in Patients with Type 2 Diabetes (T2D)" will be presented by Michaela Diamant, M.D. on Monday, June 27 at 9:00 AM PT.
2. Oral: "Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-naïve Patients with Type 2 Diabetes (DUR-4)" will be presented by David Russell-Jones, M.D. on Monday, June 27 at 9:45 AM PT.
3. Late Breaking Poster: "Safety and Efficacy of Once-Monthly Exenatide Over 20 Weeks in Patients with Type 2 Diabetes" will be presented by Leigh MacConell, Ph.D. during a poster session on Sunday, June 26 from 12:00 – 2:00 PM PT.
4. Poster: "Exenatide Once Weekly Did Not Affect Corrected QT Interval in Patients with Type 2 Diabetes" will be presented by Philip Sager, M.D. during a poster session on Saturday, June 25 from 11:30 AM – 1:30 PM PT.
5. Poster: "Exenatide Once Weekly: Sustained Improvement in Glycemic Control and Weight Loss Through 3 Years" will be presented by Leigh MacConell, Ph.D. during a poster session on Saturday, June 25 from 11:30 AM – 1:30 PM PT.
6. Poster: "Efficacy and Safety of Exenatide Once Weekly Across Background Therapies: A Pooled Analysis of DURATION Studies" will be presented by James Malone, M.D. during a poster session on Saturday, June 25 from 11:30 AM – 1:30 PM PT.
7. Poster: "The Risk of Heart Failure Among Patients Receiving Exenatide Versus Other Glucose-Lowering Medications for Type 2 Diabetes: A Matched Retrospective Cohort Analysis of the GE Healthcare Electronic Medical Record Database" will be presented by Jennie Best, Ph.D. during a poster session on Saturday, June 25 from 11:30 AM – 1:30 PM PT.
8. Poster: "Weight Change in Placebo- and Exenatide (BID)-Treated Subjects with Type 2 Diabetes on Insulin Glargine: Effects of Sex, Diabetes Duration, Baseline A1C, and Insulin Dose" will be presented by John Buse, M.D. during a poster session on Saturday, June 25 from 11:30 AM – 1:30 PM PT.
9. Poster: "Effects of Pramlintide in Patients with T2DM Using Larger Doses of Insulin – A Tertile Analysis Based on Daily Insulin Dose" will be presented by Kathrin Herrmann, Ph.D. during a poster session on Saturday, June 25 from 11:30 AM – 1:30 PM PT.
10. Poster: "Efficacy and Safety of Adjunctive Subcutaneous Injections of Pramlintide in Patients with Type 1 Diabetes Using Insulin Pumps" will be presented by Kathrin Herrmann, Ph.D. during a poster session on Saturday, June 25 from 11:30 AM – 1:30 PM PT.